News Archive

March 2015

• Media ReleaseMar 30, 2015

  Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload

  Jadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation   Jadenu, taken with or without food, simplifies daily treatment…
• 
  StoryMar 30, 2015 Discovery

  New recruit has big dreams for cancer immunotherapy

  Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.

• Media ReleaseMar 30, 2015

  Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group

  Collaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway  Addition of STING agonists further enhances…
• Media ReleaseMar 21, 2015

  Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients

  After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1]  New data at AAD shows 7 out of 10 psoriasis patients, who…
• Media ReleaseMar 20, 2015

  New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients

  CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements…
• 
  StoryMar 19, 2015 Patient Perspectives

  Psoriasis: The story of a hidden condition

  More than 125 million people worldwide live with psoriasis, a chronic autoimmune disease that causes red, scaly patches to appear on the skin.

• Media ReleaseMar 17, 2015

  Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer

  Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea  PV is a rare blood cancer associated with…
• 
  StoryMar 16, 2015 From Our Labs

  Turning up the heat on tumors
• Media ReleaseMar 13, 2015

  Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin

  Detailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1]  New data from the long-term Phase III program to…
• 
  StoryMar 09, 2015 From Our Labs

  Vision hacker

  Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.

• 
  StoryMar 09, 2015 Discovery

  Let there be sight
• Media ReleaseMar 06, 2015

  FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz

  Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…